Navigation Links
Tiens Biotech Group (USA) Reports First Quarter Results
Date:5/17/2010

5,379,312 Inventories 5,024,331 5,328,052 Other receivables 902,216 995,657 Other receivables - related parties 39,458,619 44,561,626 Employee advances 101,755 115,673 Prepaid expenses 594,263 658,193 Prepaid taxes 171,715 407,534 Total current assets 66,371,822 69,294,375 PROPERTY, PLANT AND EQUIPMENT, net 9,811,115 10,124,483 OTHER ASSETS: Construction in progress 133,225,733 125,572,621 Construction deposits 3,763,996 1,405,997 Intangible assets, net 12,789,812 12,864,295 Other assets 13,400,435 11,847,937 Total other assets 163,179,976 151,690,850 Total assets $239,362,913 $231,109,708 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $4,211,661 $5,012,157 Advances from customers - related parties 8,461,804 4,426,751 Wages and benefits payable 1,068,256 1,484,852 Income taxes payable 314,266 -- Contractor deposits 183,420 183,395 Contractor payables 18,834,263 18,513,216 Other payables 1,168,820 1,151,551 Other payables - related parties 4,405,557 3,326,110 Total current liabilities 38,648,047 34,098,032 NON-CURRENT LIABILITIES Deferred income 11,2
'/>"/>
SOURCE Tiens Biotech Group (USA), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
2. Tiens Biotech Group (USA) Reports First Quarter Results
3. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
4. eFuture Signs Contract to Provide Tiens Group with Retail Business Management System
5. Tiens Biotech Group (USA) Reports Fourth Quarter and Twelve-Month Results
6. Cutting-Edge Vaccine Research to be Showcased at AAPS National Biotechnology Conference
7. Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership
8. BioCrossroads Invests in Indianapolis Biotech Company Developing Treatments for Alzheimers Disease
9. TriLink BioTechnologies, Inc. Launches New Website and OligoBuilder(R)
10. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
11. IMBiotechnologies Receives FDA Clearance to Market Occlusin(R) 500 Biodegradable Microspheres in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 29, 2015 A ... acquiring, rapidly developing and commercialising innovative medicines ...   Highly experienced management team; blue chip ...   Mereo BioPharma Group Ltd ("Mereo"), a ... $119m ( c. £76.5m), gross, from blue chip institutional ...
(Date:7/28/2015)... 28, 2015 Seahorse Bioscience, the industry ... the provider of XF Technology which is increasingly ... areas. As the links between mitochondrial function and ... is escalating rapidly.   Recently, 12 ... Publishing Group (NPG) featuring XF Technology, including Nature, ...
(Date:7/28/2015)... Deerfield Management Company, L.P. today announced the ... will invest in groundbreaking advancements in science that may ... orphan diseases. The venture capital fund will also back ... and improve the way healthcare is delivered to patients. ... venture funds in the sector, will donate all profits ...
(Date:7/28/2015)... PRUSSIA, Pa. , July 28, 2015 ... Food and Drug Administration has accepted for review the ... recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment of ... all primary endpoints. Hemophilia A ... or defective factor VIII; nearly all affected patients are ...
Breaking Biology Technology:Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3
... to design computer chips and electronic circuitry for extreme ... electrical engineers at Vanderbilt University has developed all the ... thin films of nanodiamond. They have created diamond versions ... a key element in computers., "Diamond-based devices have the ...
... Mass., Aug. 4, 2011 Interleukin Genetics, Inc. ... call and Webcast on Friday, August 12 at 9:30 a.m. ... To access the live call, dial 877-324-1976 (domestic) or 631-291-4550 ... will be available on the Investors section of Interleukin Genetics, ...
... N.J., Aug. 4, 2011 Palatin Technologies, Inc. (NYSE ... of a Phase 1 clinical trial of AZD2820, a ... a single-agent therapy for the treatment of obesity. AZD2820 ... collaborative research program with Palatin Technologies. Obesity ...
Cached Biology Technology:Designing diamond circuits for extreme environments 2Designing diamond circuits for extreme environments 3Interleukin Genetics, Inc. Announces Conference Call to Discuss Second Quarter 2011 Results 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 2Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca 3
(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/24/2015)... , June 24, 2015 The biologics ... The major drivers for the market include growth of ... of new drug launches. Over the years, the number ... Between 2001 and 2010, the FDA approved 225 drug ... to WIPO, Europe accounted for ...
(Date:6/24/2015)... , June 24, 2015 Biometry authentication ... emerging biometric password solution one face in. ... one face in, entering the expanding ... and affordable multifactor-authentication biometric answer to the password ... provided in partnership with KeyLemon, one face in ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... MD The Federation of American Societies for ... for the Science Research Conference (SRC): Neural Mechanisms ... Research Conference, Neural Mechanisms in Cardiovascular Regulation, is ... focus on neural mechanisms that regulate normal cardiovascular ...
... Federation of American Societies for Experimental Biology (FASEB) ... Research Conference (SRC): Matricellular Proteins in Development, Health, ... surrounding extracellular matrix (ECM) are the basis for ... organization in all metazoan organisms. Structural ECM components ...
... Bethesda, MD The Federation of American Societies ... registration for the Science Research Conference (SRC): Hematologic ... Malignancies is an important and unique scientific conference ... and myeloma is presented in detail in the ...
Cached Biology News:FASEB SRC announces conference: Matricellular Proteins in Development, Health, and Disease 2
Quartz-Halogen, 100 W, High Intensity...
... System with Gateway™ Technology is designed ... the polyhedrin promoter. The expression cassette ... (bacmid DNA) by site-specific transposition (Tn7) ... recombinant bacmid DNA is then used ...
...
... Immunogen: Synthetic peptide derived from ... and bovine Math-2. Specificity: Specific ... Human Rat (positive controls: human U251 ... lysates and rat brain homogenates)Storage: Store ...
Biology Products: